EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prophylactic Vancomycin in the Primary Prevention of Clostridium difficile in Allogeneic Stem Cell Transplant

Brendon Fusco iD, Jasmine Tomita-Barber, Natale Mazzaferro, Anne Tyno, Nicole McEntee, Patricia Greenberg, Roger Strair, Dale Schaar, Dennis Cooper

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.70025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Brendon Fusco und 8 weiteren Autor:innen. Beteiligte Einrichtung: Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, New York, USA. Hauptthemen laut MEDLINE: Vancomycin, Clostridioides difficile, Anti-Bacterial Agents, Clostridium Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clostridium difficile ( C. difficile ) infection is a frequent complication following hematopoietic stem cell transplant, contributing to increased morbidity in this population. Despite current infection prevention strategies, rates among posttransplant patients at some centers remain high. Oral vancomycin is a safe and well‐tolerated antibiotic that may be a potential adjunct to prevent C. difficile .

Objectives

To evaluate the effectiveness of oral vancomycin in preventing C. difficile among allogeneic stem cell transplant patients and assess other posttransplant outcomes. Study Design A retrospective cohort study was conducted comparing the rate of C. difficile following allogeneic transplant in patients who received oral vancomycin versus no prophylaxis during hospitalization. The primary outcome was the development of C. difficile infection within the first 100 days following transplant, defined as a positive stool toxin assay or PCR. Secondary outcomes included hospital length of stay, hospital‐acquired infections, overall mortality, graft‐versus‐host disease (GVHD), and rehospitalization.

Results

Among the 202 patients, one case of C. difficile occurred in the prophylaxis group (1/71, 1.4%) compared to 31 cases in the unexposed group (31/131, 23.6%). Patients who received prophylaxis were significantly less likely to develop C. difficile infection during the study period (OR 0.046, p = 0.003). No differences were observed between groups in hospital‐acquired infections, mortality, incidence of acute GVHD, and rehospitalization.

Conclusion

Prophylactic vancomycin was associated with a marked reduction in C. difficile infection in allogeneic transplant patients. Despite no significant impact on other clinical outcomes, there was a significant reduction in symptomatic C. difficile infection. Further prospective studies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VancomycinClostridioides difficileAnti-Bacterial AgentsClostridium InfectionsHematopoietic Stem Cell TransplantationAntibiotic ProphylaxisHumansRetrospective StudiesMaleFemaleMiddle AgedAdultTransplantation, HomologousAgedGraft vs Host DiseaseCross InfectionAdministration, OralPrimary PreventionLength of Stay

Stichwörter der Autor:innen

Clostridium difficileallogeneic stem cell transplantprimary preventionprophylaxisvancomycin

Substanzen

VancomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, New York, USA.
  • Department of Internal Medicine, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, New Jersey, USA.
  • Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway Township, New Jersey, USA.
  • Robert Wood Johnson School of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.

ORCID-Profile: Brendon Fusco

Zitieren

APA

Fusco, B., Tomita-Barber, J., Mazzaferro, N., Tyno, A., McEntee, N., Greenberg, P., Strair, R., Schaar, D., & Cooper, D. (2025). Prophylactic Vancomycin in the Primary Prevention of Clostridium difficile in Allogeneic Stem Cell Transplant. Transplant Infectious Disease. https://doi.org/10.1111/tid.70025

Vancouver

Fusco B, Tomita-Barber J, Mazzaferro N, Tyno A, McEntee N, Greenberg P, et al. Prophylactic Vancomycin in the Primary Prevention of Clostridium difficile in Allogeneic Stem Cell Transplant. Transplant Infectious Disease. 2025. doi:10.1111/tid.70025

BibTeX
@article{Fusco2025,
  author = {Fusco, Brendon and Tomita-Barber, Jasmine and Mazzaferro, Natale and Tyno, Anne and McEntee, Nicole and Greenberg, Patricia and Strair, Roger and Schaar, Dale and Cooper, Dennis},
  title = {Prophylactic Vancomycin in the Primary Prevention of Clostridium difficile in Allogeneic Stem Cell Transplant},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.70025}
}
Kostenlos starten →